Azole Susceptibility and Resistance Mechanisms Surveys in Pathogenic Fungi by the CARST-fungi (2023-2024)

NCT06969703 | Not Yet Recruiting

• 1 other identifier: 2024Res301-001
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The China Antifungal Resistance Surveillance Trial (CARST-fungi) study, which has been starting in July 2019, is a multi-center, prospective, observational, and laboratory-based study of pathogenic fungal isolates causing IFDs. All fungal isolates recovered from clinical samples will be collected. For each episode of fungal isolation, the information including the patient's age, gender, the ward location, the time of sample collection, and specimen type will be collected. All isolates will be sent to the Research Center for Medical Mycology, Beijing, China, for further study including species identification and azole susceptibility testing. Azole-resistant mechanisms will be elucidated by gene sequencing or expression level assay for resistance-related genes.

Conditions

Fungal Disease

Keywords

Azole susceptibility; pathogenic fungi; resistance mechanisms; Resistance Surveillance

Outcome Measures

Primary Outcomes (1)

• The type and spectrum of azole-resistance in the pathogenic fungi

  By the end of Dec. 2025

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The individuals with fungal disease

You may qualify if:

• fungal disease

You may not qualify if:

• non-fungal disease

Sponsors & Collaborators

• Peking University First Hospital: lead

Study Sites (1)

Peking University First Hospital

Beijing, 100034, China

Location

Related Publications (2)

• Bassetti M, Garnacho-Montero J, Calandra T, Kullberg B, Dimopoulos G, Azoulay E, Chakrabarti A, Kett D, Leon C, Ostrosky-Zeichner L, Sanguinetti M, Timsit JF, Richardson MD, Shorr A, Cornely OA. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017 Sep;43(9):1225-1238. doi: 10.1007/s00134-017-4731-2. Epub 2017 Mar 2.

  PMID: 28255613 BACKGROUND

• Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia. 2012 Oct;174(4):259-71. doi: 10.1007/s11046-012-9551-x. Epub 2012 May 13.

  PMID: 22580756 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

All the fungal isolates from the sterile sites, including blood, ascitic fluid, pleural fluid, cerebrospinal fluid, and pus, bronchoalveolar lavage fluid (BALF), central venous catheter (CVC) tips, biliary tract fluid and tissues of patients with invasive yeast infections.

MeSH Terms

Conditions

Mycoses

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Study Officials

• Wei Liu

  Peking University First Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Wei Liu, M.D., Ph.D.

CONTACT

86-10-83573075; liuwei@bjmu.edu.cn

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2025
• First Posted: May 14, 2025
• Study Start: June 10, 2025
• Primary Completion: September 15, 2025
• Study Completion: September 30, 2025
• Last Updated: May 14, 2025

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP

Locations

CN (1)